Nanjing Well Pharmaceutical GroupLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Renrong Wu
Chief executive officer
CN¥990.7k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.6yrs |
| CEO ownership | 13.7% |
| Management average tenure | no data |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality
Aug 26
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's
Jun 07Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings
Jun 06CEO
Renrong Wu (61 yo)
4.6yrs
Tenure
CN¥990,700
Compensation
Mr. Renrong Wu is Chairman, Director & CEO of Nanjing Well Pharmaceutical Group Co.,Ltd. from April 08, 2020. He joined the Nanjing Well Pharmaceutical Group Co.,Ltd.in February 2000.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.6yrs | CN¥990.70k | 13.68% CN¥ 445.8m | |
| Director | 4.6yrs | CN¥825.60k | 10.42% CN¥ 339.7m | |
| Director & VP | 4.6yrs | CN¥825.60k | 10.42% CN¥ 339.7m | |
| Independent Director | 1.5yrs | CN¥49.70k | no data | |
| Chairman of the Supervisory Board | 4.6yrs | no data | 2.2% CN¥ 71.7m |
4.6yrs
Average Tenure
58yo
Average Age
Experienced Board: 603351's board of directors are considered experienced (4.6 years average tenure).